Goody Robin J, Oakley Sarah M, Filliol Dominique, Kieffer Brigitte L, Kitchen Ian
Pharmacology Group, School of Biomedical and Life Sciences, University of Surrey, Guilford, Surrey GU2 7XH, UK.
Brain Res. 2002 Jul 26;945(1):9-19. doi: 10.1016/s0006-8993(02)02452-6.
Using quantitative receptor autoradiography we have determined if deletion of the delta-opioid receptor gene (Oprd1) results in compensatory changes in the expression of other opioid receptors. Gene targeting was used to delete exon 1 of the mouse delta-opioid receptor gene and autoradiography was carried out on brains from wild-type, heterozygous and homozygous knockout mice. Delta-opioid receptors were labeled with [(3)H]deltorphin I (7 nM), mu- with [(3)H]DAMGO (4 nM), and kappa- with [(3)H]CI-977 (2.5 nM) or [(3)H]bremazocine (2 nM in the presence of DPDPE and DAMGO) and non-specific binding determined with naloxone. [(3)H]Deltorphin I binding was reduced by approximately 50% in heterozygous animals. In homozygous animals specific binding could only be detected after long-term film exposure (12 weeks). Regions exhibiting this residual [(3)H]deltorphin I binding correlated significantly with those demonstrating high levels of the mu-receptor and were abolished in the presence of the mu-agonist DAMGO. Autoradiographic mapping showed significant overall reductions in [(3)H]DAMGO and [(3)H]CI-977 binding throughout the brain following loss of both copies of the Oprd1 gene. In contrast, overall levels of [(3)H]bremazocine binding were higher in brains from -/- than +/+ mice. Our findings suggest that residual [(3)H]deltorphin I binding in the brain of delta-receptor gene knockout mice is the result of cross-reactivity with mu-sites and that there are no delta-receptor subtypes derived from a different gene. Changes in mu- and kappa-receptor labeling suggest compensatory changes in these subtypes in response to the absence of the delta-receptor. The differences in [(3)H]CI-977 and [(3)H]bremazocine binding indicate these ligands show differential recognition of the kappa-receptor.
我们使用定量受体放射自显影技术来确定δ-阿片受体基因(Oprd1)的缺失是否会导致其他阿片受体表达的代偿性变化。采用基因打靶技术删除小鼠δ-阿片受体基因的外显子1,并对野生型、杂合子和纯合子敲除小鼠的脑进行放射自显影。用[(3)H]Deltorphin I(7 nM)标记δ-阿片受体,[(3)H]DAMGO(4 nM)标记μ-阿片受体,[(3)H]CI-977(2.5 nM)或[(3)H]布瑞马唑辛(在存在DPDPE和DAMGO的情况下为2 nM)标记κ-阿片受体,并用纳洛酮测定非特异性结合。[(3)H]Deltorphin I结合在杂合子动物中减少了约50%。在纯合子动物中,只有经过长期胶片曝光(12周)才能检测到特异性结合。显示这种残留[(3)H]Deltorphin I结合的区域与显示高水平μ-受体的区域显著相关,并且在存在μ-激动剂DAMGO的情况下消失。放射自显影图谱显示,在Oprd1基因的两个拷贝缺失后,整个大脑中[(3)H]DAMGO和[(3)H]CI-977结合显著总体减少。相比之下,-/-小鼠脑内[(3)H]布瑞马唑辛结合的总体水平高于+/+小鼠。我们的研究结果表明,δ-受体基因敲除小鼠脑中残留的[(3)H]Deltorphin I结合是与μ-位点交叉反应的结果,并且不存在源自不同基因的δ-受体亚型。μ-和κ-受体标记的变化表明这些亚型在δ-受体缺失时发生了代偿性变化。[(3)H]CI-977和[(3)H]布瑞马唑辛结合的差异表明这些配体对κ-受体表现出不同的识别。